Market Overview

UPDATE: Credit Suisse Initiates Outperform, $7 PT on XenoPort; Valuation Trumps Fundamental Concerns

Related XNPT
XenoPort Reports HORIZANT Included in New Expert Recommendations on Prevention, Treatment of RLS Augmentation
Who's The Next Big Pharma Acquisition?

Credit Suisse initiates its coverage on XenoPort (NASDAQ: XNPT) with an Outperform rating and a price target of $7 per share.

Credit Suisse says, "Despite a number of fundamental concerns, at its current valuation ($219mn market cap/$165mn y/e EV) and with low expectations for its marketed products and pipeline, we think relatively little has to go right for the stock price to appreciate. Specifically we see 3 main upside optionality triggers which are not factored into our numbers/valuation (a) delivery of greater Regnite/Horizant revenues - either via high end-user sales and/or US re-partnering (b) monetization of clinical assets, in particular XP23829 or (c) the company seeks strategic alternatives."

XNPT closed at $6.07 on Wednesday.

Latest Ratings for XNPT

Jan 2015JefferiesMaintainsBuy
Apr 2014JefferiesInitiates Coverage onBuy
Jun 2013Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for XNPT
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings


Related Articles (XNPT)

Get Benzinga's Newsletters